C-kit mutation in acute myeloid leukemia patients with AML1-ETO fusion gene and its clinical significance.
10.7534/j.issn.1009-2137.2013.04.005
- Author:
Su-Xia GENG
1
;
Xin DU
;
Jian-Yu WENG
;
Xin HUANG
;
Ze-Sheng LU
;
Li-Ye ZHONG
;
Rong GUO
;
Sui-Jing WU
;
Ping WU
Author Information
1. Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Core Binding Factor Alpha 2 Subunit;
genetics;
DNA Mutational Analysis;
Female;
Humans;
Leukemia, Myeloid, Acute;
genetics;
pathology;
Male;
Middle Aged;
Mutation;
Oncogene Proteins, Fusion;
genetics;
Prognosis;
Proto-Oncogene Proteins c-kit;
genetics;
RUNX1 Translocation Partner 1 Protein;
Treatment Outcome;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(4):839-842
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the c-kit mutation in acute myeloid leukemia (AML) patients with AML1-ETO and analyze its relation with clinical and laboratorial features and prognosis. PCR and sequencing methods were used to detect the c-kit 17 exon mutations in 31 AML patients with AML1-ETO. The relation of the c-kit mutation with clinical features, results of laboratorial examination and prognosis of disease were analyzed. The results showed that the c-kit mutation was found in 14 out of 31 AML patients and the mutation frequency was 45.16%. Male patients had a higher incidence of c-kit mutation than that of female patients (P = 0.020). The proportion of patients with newly diagnosed white blood cell>10×10(9)/L and with extramedullary infiltration in mutated group were higher than those in unmutated group respectively. No significant difference was observed at the age (P = 0.437) and the rate of bone marrow blasts(P = 0.510) between the above mentioned two groups. The difference in complete remission rate (64.29% vs 80%, P = 0.344)and relapse rate (58.33% vs 21.43%, P = 0.054) between c-kit mutated and c-kit unmutated groups were not significant. While the c-kit mutated group had a significant higher death rate as compared with c-kit unmutated group (57.14% vs 20%, P = 0.039). It is concluded that the c-kit mutation is frequent in AML patients with AML1-ETO and the c-kit mutated patients have a poor prognosis. It is important to detect c-kit mutation in routine clinical practice for patient's risk stratification, evaluation of prognosis and selection of effective treatment.
